Macquarie Group’s Surface Oncology, Inc. Common Stock SURF Stock Holding History

Macquarie Group’s Portfolio SURF Stock Details SURF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-350,000	Closed	-$304K	–	1715
2023 Q2	$304K	Hold	350,000	–	–	﹤0.01%	1511
2023 Q1	$245K	Hold	350,000	–	–	﹤0.01%	1538
2022 Q4	$287K	Hold	350,000	–	–	﹤0.01%	1567
2022 Q3	$364K	Hold	350,000	–	–	﹤0.01%	1566
2022 Q2	$574K	Hold	350,000	–	–	﹤0.01%	1572
2022 Q1	$1.03K	Hold	350,000	–	–	﹤0.01%	1544
2021 Q4	$1.67M	Hold	350,000	–	–	﹤0.01%	1422
2021 Q3	$2.65M	Hold	350,000	–	–	﹤0.01%	1292
2021 Q2	$2.61M	Hold	350,000	–	–	﹤0.01%	1333
2021 Q1	$2.73M	Hold	350,000	–	–	﹤0.01%	1081
2020 Q4	$3.23M	Buy	+350,000	New	+$3.04M	﹤0.01%	973

Macquarie Group's SURF Position: Q3 2023 in Review

Macquarie Group sold out of Surface Oncology, Inc. Common Stock (SURF) in Q3 2023, closing a stake of 350,000 shares — an estimated $304K sold.

Macquarie Group first reported a position in SURF in Q4 2020 and held it in 11 quarters. The position peaked at $3.23M in Q4 2020. 0 funds tracked by Wall St. Rank hold SURF as of Q3 2023.

Macquarie Group reported no remaining Surface Oncology, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Macquarie Group sold 350,000 Surface Oncology, Inc. Common Stock shares in Q3 2023, an estimated $304K.
Macquarie Group first reported a position in Surface Oncology, Inc. Common Stock in Q4 2020 and held it in 11 quarters.
Macquarie Group's Surface Oncology, Inc. Common Stock position peaked at $3.23M in Q4 2020.
0 funds tracked by Wall St. Rank held Surface Oncology, Inc. Common Stock as of Q3 2023.

Based on Macquarie Group's 13F filing for Q3 2023, filed 14 Nov 2023.